Evoke Pharma (EVOK) and Innocoll Holdings PLC (INNL) Head to Head Analysis
Evoke Pharma (NASDAQ: EVOK) and Innocoll Holdings PLC (NASDAQ:INNL) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings and valuation.
Institutional & Insider Ownership
12.9% of Evoke Pharma shares are held by institutional investors. Comparatively, 34.2% of Innocoll Holdings PLC shares are held by institutional investors. 20.0% of Evoke Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Evoke Pharma and Innocoll Holdings PLC’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Innocoll Holdings PLC||N/A||N/A||N/A||($1.67)||-1.41|
Evoke Pharma is trading at a lower price-to-earnings ratio than Innocoll Holdings PLC, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Evoke Pharma has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Comparatively, Innocoll Holdings PLC has a beta of -0.3, meaning that its stock price is 130% less volatile than the S&P 500.
This is a breakdown of current ratings for Evoke Pharma and Innocoll Holdings PLC, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Innocoll Holdings PLC||0||3||1||0||2.25|
Evoke Pharma presently has a consensus price target of $8.20, suggesting a potential upside of 237.45%. Innocoll Holdings PLC has a consensus price target of $4.50, suggesting a potential upside of 91.49%. Given Evoke Pharma’s stronger consensus rating and higher possible upside, equities analysts plainly believe Evoke Pharma is more favorable than Innocoll Holdings PLC.
This table compares Evoke Pharma and Innocoll Holdings PLC’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Innocoll Holdings PLC||-1,051.20%||N/A||-138.53%|
Evoke Pharma beats Innocoll Holdings PLC on 8 of the 10 factors compared between the two stocks.
Evoke Pharma Company Profile
Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. EVK-001 is a formulation of Metoclopramide drug, designed to provide systemic delivery of metoclopramide through intranasal administration. The Company has evaluated EVK-001 in a multicenter, randomized, double-blind, placebo-controlled parallel group, dose-ranging Phase IIb clinical trial. The Company has commenced a Phase III clinical trial of EVK-001 in female patients with symptoms associated with acute and recurrent diabetic gastroparesis. The Phase III clinical trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy, safety and population pharmacokinetics of EVK-001 in adult females.
Innocoll Holdings PLC Company Profile
Innocoll Holdings Public Limited Company is a commercial-stage specialty pharmaceutical and medical device company with late-stage development programs. The Company operates through the segment of manufacture and sale of collagen-based pharmaceutical products. It utilizes collagen-based technology platform to develop its biodegradable and bioresorbable products and product candidates, which can be broken down by the body without the need for surgical removal or applied topically. Using its processes at its manufacturing facility, it derives and purifies bovine and equine collagen and then utilizes its technology platform to incorporate the purified collagen into its topical and implantable products. Its lead product candidates are XaraColl for the treatment of post-operative pain and Cogenzia for the treatment of diabetic foot infections. Its marketed products include CollaGUARD, Collatamp, Septocoll and RegenePro. It has initiated its Phase III efficacy trials for Cogenzia.
Receive News & Ratings for Evoke Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.